Thomas King, MBA
Chair

Thomas B. King has served as a director of the Company since 2020. Thomas brings a wealth of knowledge from 40+ years of experience in biopharma leadership positions ranging from large to development-stage companies. Thomas has built, operated and sold multiple public specialty pharmaceutical businesses. He was recently interim Executive Chair of Achieve Life Sciences, Inc., (Nasdaq: ACHV), from August 2024 to June 2025. Previously, Thomas served on the board of VIVUS, Inc. (Nasdaq: VVUS), from May 2017 to December 2020, acting as interim CEO from December 2017 to April 2018 and interim President from April to May 2018. He was President, CEO, and a board member of Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), from June 2003 to August 2016, when it was acquired by Grupo Ferrer, also serving as CFO and Chief Accounting Officer from October 2015 to August 2016. Prior to this, Thomas was President, CEO and a board member of Cognetix, Inc., a privately held biopharmaceutical company, from September 2002 to April 2003. At Anesta Corporation (Nasdaq: NSTA), he held various senior roles, including President and COO (1995-1997) and President and CEO (1997-2000), and served on the board until its acquisition by Cephalon, Inc. (Nasdaq: CEPH) in October 2000.

Thomas is also currently Board Chair of Achieve, joining the board in March 2023.

He received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.